Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) was down 4% during trading on Wednesday . The company traded as low as $8.30 and last traded at $8.30, with a volume of 64,878 shares trading hands. The stock had previously closed at $8.65.

A number of equities research analysts recently commented on FOMX shares. Guggenheim reissued a “buy” rating and set a $10.00 target price on shares of Foamix Pharmaceuticals in a research report on Tuesday, May 10th. Zacks Investment Research raised shares of Foamix Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.75 target price for the company in a research report on Tuesday, August 16th. Finally, TheStreet raised shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 2nd.

The company’s market capitalization is $254.49 million. The stock has a 50-day moving average price of $7.99 and a 200-day moving average price of $6.83.

Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.02. The business had revenue of $1.50 million for the quarter, compared to analyst estimates of $1.10 million. Equities analysts expect that Foamix Pharmaceuticals Ltd. will post ($0.92) EPS for the current year.

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.